{"nctId":"NCT02157974","briefTitle":"Liver and Fat Regulation in Overweight Adolescent Girls","startDateStruct":{"date":"2014-08","type":"ACTUAL"},"conditions":["Hepatic Steatosis","Polycystic Ovarian Syndrome","Obesity"],"count":92,"armGroups":[{"label":"PCOS, medication naive + Byetta","type":"EXPERIMENTAL","interventionNames":["Drug: Byetta 5Mcg Pen Injection"]},{"label":"Control","type":"NO_INTERVENTION","interventionNames":[]},{"label":"PCOS medication naive","type":"NO_INTERVENTION","interventionNames":[]},{"label":"PCOS on COCPs","type":"NO_INTERVENTION","interventionNames":[]},{"label":"PCOS on metformin","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Byetta 5Mcg Pen Injection","otherNames":["Exenatide"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Females\n* 2 years post-menarche\n* BMI percentile \\>90%\n\nExclusion Criteria:\n\n* Type 2 diabetes\n* Anemia\n* Liver disease\n* Medications known to effect insulin sensitivity\n* Cause of oligomenorrhea or hirsutism other than PCOS,\n* \\>3 hours a week of moderate exercise.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"12 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hepatic Glucose Release","description":"Hepatic glucose release will be measured by the rate of appearance of a glucose tracer. Glucose rate of appearance reflects the amount of glucose being release by primarily the liver during fasting. A higher glucose rate of appearance is often seen with dysglycemia","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"1.24"},{"groupId":"OG001","value":"1.46","spread":"0.21"},{"groupId":"OG002","value":"1.54","spread":"0.38"},{"groupId":"OG003","value":"1.88","spread":"0.49"},{"groupId":"OG004","value":"1.57","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Hepatic Phosphate Concentrations","description":"Hepatic phosphate relative concentrations will be measured with 31 phosphorus magnetic resonance spectroscopy. The ratio of the following will be reported over total phosphate concentration: Phosphodiesterase (PDE), phosphomonoester (PME), Adenosine triphosphate (ATP), Inorganic Phosphate (Pi),Nicotinamide adenine dinucleotide phosphate (NADPH), Uridine diphosphate glucose (UDPG)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.167684728","spread":"0.056413082"},{"groupId":"OG002","value":"0.198640255","spread":"0.040933351"},{"groupId":"OG003","value":"0.198787476","spread":"0.045832565"},{"groupId":"OG004","value":"0.186923469","spread":"0.039481266"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.067905319","spread":"0.033816456"},{"groupId":"OG002","value":"0.077949656","spread":"0.02943916"},{"groupId":"OG003","value":"0.075872089","spread":"0.024970918"},{"groupId":"OG004","value":"0.066789803","spread":"0.036986035"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.592517535","spread":"0.038294886"},{"groupId":"OG002","value":"0.566952309","spread":"0.061717281"},{"groupId":"OG003","value":"0.565157308","spread":"0.042119495"},{"groupId":"OG004","value":"0.557277652","spread":"0.034367129"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.041945761","spread":"0.02076513"},{"groupId":"OG002","value":"0.054581135","spread":"0.019288097"},{"groupId":"OG003","value":"0.046604505","spread":"0.022669904"},{"groupId":"OG004","value":"0.074459672","spread":"0.021584936"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.097201285","spread":"0.043438464"},{"groupId":"OG002","value":"0.068550332","spread":"0.028503778"},{"groupId":"OG003","value":"0.067305736","spread":"0.033620062"},{"groupId":"OG004","value":"0.074693726","spread":"0.021031863"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.032745372","spread":"0.011777685"},{"groupId":"OG002","value":"0.033326313","spread":"0.014030497"},{"groupId":"OG003","value":"0.046272886","spread":"0.023894603"},{"groupId":"OG004","value":"0.039855678","spread":"0.012418624"}]}]}]},{"type":"SECONDARY","title":"Rates of Lipolysis","description":"Rate of lipolysis will be measured by the rate of appearance of a glycerol tracer. Glycerol rate of appearance reflects the amount of glycerol being released into the blood stream as a results of lipolysis. Higher rates of lipolysis are thought to be associated with insulin resistance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"0.17"},{"groupId":"OG001","value":"0.49","spread":"0.22"},{"groupId":"OG002","value":"0.49","spread":"0.24"},{"groupId":"OG003","value":"0.78","spread":"0.18"},{"groupId":"OG004","value":"0.65","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Hepatic Fat Fraction","description":"Amount of fat in the liver measured by MRI and calculated via the Dixon method as the proton density hepatic fat fraction, which ranges from 0-75%. Greater than 5% is considered extra fat in the liver.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"3.1"},{"groupId":"OG001","value":"7.6","spread":"6.3"},{"groupId":"OG002","value":"6.9","spread":"5.3"},{"groupId":"OG003","value":"6.8","spread":"9.4"},{"groupId":"OG004","value":"13.3","spread":"12.1"}]}]}]},{"type":"SECONDARY","title":"Hepatic de Novo Lipogenesis","description":"Hepatic de novo lipogenesis will be measured by with an acetate tracer by mass spectroscopy. De novo lipogenesis can contribute to non-alcoholic fatty liver disease, so having a lower value is better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":"5.3"},{"groupId":"OG001","value":"6.6","spread":"4.2"},{"groupId":"OG002","value":"7.9","spread":"7.2"},{"groupId":"OG003","value":"18.2","spread":"14.9"},{"groupId":"OG004","value":"19.4","spread":"17.4"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Whole Body Insulin Sensitivity","description":"Participants will undergo a 75 gram oral glucose tolerance test, and whole body insulin sensitivity will be expressed as Si, calculated via the oral minimal model using SAMM II software. This software uses participant weight, glucose and insulin concentrations at various time points during the oral glucose tolerance test to calculate the participant insulin sensitivity. The higher the Si value means more insulin sensitivity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000319383","spread":"0.00021025"},{"groupId":"OG001","value":"0.00021077","spread":"0.000275814"},{"groupId":"OG002","value":"0.00033516","spread":"0.000366279"},{"groupId":"OG003","value":"0.00021791","spread":"0.000255919"},{"groupId":"OG004","value":"0.0000959833333","spread":"0.0000414436685"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Sleep Quality","description":"Apnea Hypopnea Index (AHI) will be measured using WatchPAT. In children and adolescents the scale that will be used is AHI\\>5 is considered mild sleep apnea. The higher the AHI, indicates more severe sleep apnea.\n\nThe AHI is the number of times you have apnea or hypopnea during one night, divided by the hours of sleep.\n\nNormal sleep: An AHI of fewer than five events, on average, per hour Mild sleep apnea: An AHI of five to 14 events per hour Moderate sleep apnea: An AHI of 15 to 29 events per hour Severe sleep apnea: An AHI of 30 or more events per hour","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.15","spread":"4.71"},{"groupId":"OG002","value":"31.25","spread":"12.09"},{"groupId":"OG003","value":"19.32","spread":"11.85"},{"groupId":"OG004","value":"19","spread":"0.57"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Sleep Duration","description":"Sleep duration will be assessed using home actigraphy using the Philips Actigraph wrist-worn watch, and collects 7 days of data.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"430.85","spread":"48.38"},{"groupId":"OG001","value":"437.88","spread":"49.32"},{"groupId":"OG002","value":"410.3","spread":"58"},{"groupId":"OG003","value":"438.29","spread":"49.76"},{"groupId":"OG004","value":"414.87","spread":"62.29"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":24},"commonTop":[]}}}